Improving patient access to modern myeloma therapy in Latin America: first step, know what your problem really is.

Interestingly, although insurance type was a significant predictor of survival among patients that received non-transplant therapies, it did not affect survival amongst transplant recipients. Induction chemotherapy with at least three drugs (including bortezomib), followed by high-dose melphalan and autologous stem cell transplantation and maintenance therapy are considered standard of care for "transplant-eligible" MM patients. [Extracted from the article]